DECLARATION AND POWER OF ATTORNEY FOR UNITED STATES PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if more than one name is listed below) of the subject matter which is claimed and for which a United States patent is sought on the invention entitled

NEW HUMAN CATHEPSIN

the specification of which:
// is attached hereto.
/X / was filed on June 26, 1997, as application Serial No. 08/883,526 and if this box contains an X //, was amended on
// was filed as Patent Cooperation Treaty international application No on, 19, if this box contains an X /_/, was amended on under Patent Cooperation Treaty Article 19 on19_, and if this box contains an X /_/, was amended on
I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I hereby claim the benefit under Title 35, United States Code, §119 or §365(a)-(b) of any foreign application(s) for patent or inventor's certificate indicated below and of any Patent Cooperation Treaty international applications(s) designating at least one country other than the United States indicated below and have also identified below any foreign application(s) for patent or inventor's certificate and Patent Cooperation Treaty international application(s) designating at least one country other than the United States for the same subject matter and having a filing date before that of the application for said subject matter the priority of which is claimed:

I acknowledge my duty to disclose information which is material to the examination of

this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

Country	Number	Filing Date	Priority Claimed	, ,
Yes / / No				י י
/ No		· <u>·</u>	/_/ Yes	/

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in said prior application(s) in the manner required by the first paragraph of Title 35, United States Code §112, I acknowledge my duty to disclose material information as defined in Title 37 Code of Federal Regulations, §1.56(a) which occurred between the filing date(s) of the prior application(s) and the national or Patent Cooperation Treaty international filing date of this application:

Application		Status (Pending,	
Serial No.	Filed	Abandoned, Patented)	

I hereby appoint the following:

LUCY J. BILLINGS
MICHAEL C. CERRONE

Registration No. 36,749 Registration No. 39,132

respectively and individually, as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Please address all communications to:

LUCY J. BILLINGS, ESQ. INCYTE PHARMACEUTICALS, INC. 3174 PORTER DRIVE, PALO ALTO, CA 94304

TEL: 650-855-0555

FAX: 650-845-4166

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

*IMPORTANT: Before this declaration is signed, the patent application (the specification, the claims and this declaration) must be read and understood by each person signing it, and no changes may be made in the application after this declaration has been signed.

Sole Inventor or First Joint Inventor:

Full name:

OLGA BANDMAN

Signature:

There rules

Date:

United States of America

Residence:

Citizenship:

Mountain View, California

P.O. Address:

366 Anna Avenue

Mountain View, CA 94043

Second Joint Inventor:

Full name:

KARL J. GUEGI

Signature:

Date:

Switzerland

Residence:

Citizenship:

Menlo Park, California

P.O. Address:

1048 Oakland Avenue Menlo Park, CA 94025

3

Third Joint Inventor:	Full name:	NEIL C CORLEY
	Signature:	1/ef a lirly
	Date:	NOVEMBER 18, 1997
	Citizenship:	United States of America
	Residence:	Mountain View, California
	P.O. Address:	1240 Dale Avenue, #30 Mountain View, CA 94040

Fourth Joint Inventor:	Full name:	PURVI SHAH
	Signature:	- Panishal
	Date:	11/14/97
	Citizenship:	India

Residence: Sunnyvale, California

P.O. Address: 1608 Queen Charlotte Drive, #5 Sunnyvale, CA 94087 Certificate of Mailing

"Express Mail" mailing label number EL 947 441 420 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box CPA, Washington, D.C. 20231 on __December 11, 2002_.

By: Vanu Kome Printed: Nanncy Ramos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bandman et al.

Title:

NEW HUMAN CATHEPSIN

Serial No.:

09/519,283

Filing Date:

March 07, 2000

Examiner:

Fronda, C.

Group Art Unit:

1652

Box CPA

Commissioner for Patents Washington, D.C. 20231

CERTIFICATE UNDER 37 C.F.R. §3.73(b), REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Sir:

The undersigned has reviewed all the documents in the chain of title of the above-identified patent application and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Incyte Genomics, Inc., formerly known as Incyte Pharmaceuticals, Inc., having a principal place of business located at 3160 Porter Drive, Palo Alto, California 94304, certifies that it is the assignee and owner of the entire right, title and interest in, to, and under the invention described and claimed in the above-identified application by virtue of an Assignment recorded at Reel 8821, Frame 0465, hereby revokes all previous powers of attorney and appoints the following patent attorneys/agents:

Lucy J. Billings	Reg. No. 36,749
Jenny Buchbinder	Reg. No. 48,588
Diana Hamlet-Cox	Reg. No. 33,302
Joel Harris	Reg. No. 44,743
Richard C. Ekstrom	Reg. No. 37,027
Barrie D. Greene	Reg. No. 46,740
Lori L. Kerber	Reg. No. 41,113
Gina C. Nellesen	Reg. No. 52,062
Shirley A. Recipon	Reg. No. 47,016
Cathleen M. Rocco	Reg. No. 46,172
Susan K. Sather	Reg. No. 44,316
Michelle M. Stempien	Reg. No. 41,327
David G. Streeter	Reg. No. 43,168
James M. Verna	Reg. No. 33,287
Yu-Mei Eureka Wang	Reg. No. 50,510

Please direct all correspondence t:

Legal Department
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304

and direct all telephone calls and facsimile transmissions to: Diana Hamlet-Cox, Incyte Genomics, Inc., Phone: (650) 855-0555, Fax: (650) 845-4166 or (650) 849-8886.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

INCYTE GENOMICS, INC.

Date: December 11, 2002	By: by the left
	Lee Bendekgey

VP, General Counsel/Corporate Secretary

"Express Mail" mailing label number EM 181 313 429 US. 1 hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissionen for Pafents. Box Sequence, Washington, D.C. 20231 on

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Bandman et al.)	Group Art Unit: To Be Assigned
Serial No.:	To Be Assigned)	Examiner: To Be Assigned
Filed:	Herewith)	
Title: NEW HUMAN	CATHEPSIN)	

Assistant Commissioner for Patents

Box Sequence

Washington, D.C. 20231

SUBMISSION UNDER 37 CFR § 1.821-1.825 SEQUENCE LISTING

Sir:

In accordance with the requirements of 37 CFR § 1.821-1.825, Applicants hereby submit one diskette containing the computer-readable information for the Sequence Listing of the above-identified application. The diskette complies with the requirements of 37 CFR § 1.824 and is IBM PC compatible using a PC-DOS/MS-DOS 6.2 operating system with Fastseq software version 2.0.

Contained within the application, as filed, just before the claim section, is the Sequence Listing paper copy of the sequences disclosed in the application.

The content of the Sequence Listing paper copy is identical to the computer-readable copy, as required under 37 CFR § 1.821(f).

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Reg. No. 36,749

3174 Porter Drive

Palo Alto, California 94304 Phone: (415) 855-0555

Fax: (415) 845-4166